| We comply with the HONcode standard for trustworthy health information: verify here. |
Latest Leukemia Clinical TrialsJune 25, 2008 To view the latest leukemia treatment clinical trials listed by the National Cancer Institute see this link: http://www.cancer.gov/clinicaltrials. Clinical trials are studies designed to find better ways to treat mesothlioma patients. There are currently 284 trials listed just for chronic myelogenous leukemia (CML), but the number changes often as trials open and close. In the past two weeks for instance six CML trials have closed. 219 of these trials are in the United States while most of the rest are in Europe. The number of ongoing trials in the United States for different leukemias is:
There are many other diseases for which clinical trials can be found on the NCI website mentioned above. Law Suits Filed in Adult ALL Cases From Santa Maria Valley, CaliforniaNovember 21, 2007 In November of 2007 Paul & Hanley LLP filed law suits in Los Angeles superior court on behalf of two adult clients recently diagnosed with acute lymphocytic leukemia (ALL). While ALL is a common form of leukemia in the relatively small number of children who get cancer, it is rare in adults. ALL, which is also called acute lymphoblastic leukemia, is a fast-growing type of leukemia (blood cancer) in which too many lymphoblasts (immature white blood cells) are found in the blood and bone marrow. Both plaintiffs were born and raised in the Santa Maria valley in the southern part of Santa Barbara County, California and both were diagnosed within an eight month period. A third case involving adult ALL in the Santa Maria valley was filed by another firm in 2006. The plaintiffs allege that they were exposed to the hazardous "BTEX" constituents (benzene, toluene, ethylbenzene and xylene) as well as to other toxic volatile organic compounds and substances by off-gassing from abandoned oil drilling sumps and storage tanks that are common in the Santa Maria valley. These three cases of a rare cancer in an area with a population of only 82,000 have raised red flags. If you lived, or are now living, in the Santa Maria valley and have developed a serious disease like ALL, you may want to contact a toxic torts law firm like Paul & Hanley LLP. New Drug Xanafide for AML Begins Phase III TrialsNovember 14, 2007 On October 8, 2007 Xanthus Pharmaceuticals Inc., a Cambridge, Massachusettes drug development company, began the third phase of its trials for a cancer drug. Xanthus reports it is now using Xanafide (amonafide malate) for the treatment of people with secondary acute myeloid leukemia (sAML). Xanthus officials say the company plans to enroll approximately 350 patients in the trial. The primary endpoint of the study is the rate of complete remission. In April, Xanthus acquired an exclusive worldwide license to patents from Johns Hopkins University for treating immune-related disorders. Senator Baucus Pushes Medicare To Cover Anemia Drugs for Cancer PatientsOctober 23, 2007 Senate Finance Committee Chair Max Baucus (D-Mont.) on Monday introduced a bill that would reverse a CMS decision to limit Medicare coverage for use of anemia medications -- Aranesp, marketed by Amgen, and Procrit, marketed by Johnson & Johnson -- in cancer patients. According to a 61-page "national coverage determination" announced in July, Medicare will cover the medications, synthetic forms of the protein erythropoietin, to treat anemia caused by chemotherapy but not anemia caused by cancer. Under the decision, Medicare will cover the medications to treat anemia in cancer patients whose hemoglobin levels decrease to less than 10 grams per deciliter of blood. The decision will allow local Medicare contractors to determine whether to cover the medications to treat patients with myelodysplastic syndrome, a condition that can lead to leukemia. The legislation, a Congressional Review Act joint resolution that requires approval from Congress and President Bush, would require CMS to reverse the decision. According to Baucus, the decision "will prevent vulnerable cancer patients from getting the care they need." He added, "Esteemed clinicians state, and no one has refuted, that the cap set by CMS will require thousands of patients to seek blood transfusions that could have been avoided." The American Society of Clinical Oncology and the American Society of Hematology on Monday criticized the CMS decision and released new guidelines for use of anemia medications based on a three-year review of clinical trials. Clinical Trial Center for Hematologic Malignancies LaunchedOctober 9, 2007 In an effort to increase access and participation in clinical trials among adult blood cancer patients, The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute have launched a groundbreaking partnership called The Clinical Trial Center for Hematologic Malignancies. This innovative collaboration is a unique approach to making blood cancer clinical trials available to patients in their community so they can easily have access to the newest treatments for leukemia, lymphoma and myeloma.
|
|||